Patient with M1d melanoma treated with encorafenib and binimetinib with partial response in the second line
Abstract
The presence of brain metastases in patients diagnosed with melanoma is associated with a dismal prognosis. The
implementation of modern therapies (a combination of BRAF-MEK inhibitors and anti-CTLA-4 with anti-PD-1), has
resulted in unprecedented improvements in the treatment of such patients. The presented case of a 40-year-old
patient diagnosed with melanoma disseminated to the brain, with negative prognostic factors, is an example of
a milestone in oncology. The combination of systemic treatment and radio- therapy makes it possible to achieve
disease control in the central nervous system. It is worth emphasizing that such a patient should be treated with
a multidisciplinary approach in comprehensive cancer centers.
Keywords: melanomabrain metastasestargeted therapyradiotherapy
References
- Phadke M, Ozgun A, Eroglu Z, et al. Melanoma brain metastases: Biological basis and novel therapeutic strategies. Exp Dermatol. 2022; 31(1): 31–42.
- Rutkowski P, Kiprian D, Dudzisz-Śledź M, et al. Postępowanie w przerzutach czerniaka do mózgowia. Onkologia w Praktyce Klinicznej - Edukacja. Onkologia w Praktyce Klinicznej - Edukacja. 2019; 5(1): 54–65.
- Bander ED, Yuan M, Carnevale JA, et al. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. Cancer. 2021; 127(12): 2062–2073.
- Becco P, Gallo S, Poletto S, et al. Melanoma Brain Metastases in the Era of Target Therapies: An Overview. Cancers (Basel). 2020; 12(6).
- Internò V, Sergi MC, Metta ME, et al. Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies. Cancers (Basel). 2023; 15(5).
- Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021; 22(12): 1692–1704.
- Tan XL, Le A, Lam FC, et al. Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma. Front Oncol. 2022; 12: 885472.
- Hilbers ML, Dimitriou F, Lau P, et al. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. Eur J Cancer. 2021; 156: 149–163.
- Tawbi HA, Forsyth PA, Hodi FS, et al. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021; 23(11): 1961–1973.
- Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017; 18(7): 863–873.
- Marquez-Rodas I, Arance A, Guerrero MAB, et al. 1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial. Annals of Oncology. 2021; 32: S870.
- Davies MA, Weber JS, Flaherty KT, et al. A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS). Annals of Oncology. 2019; 30: v562–v563.
- Marquez-Rodas I, Fernandez AMA, Guerrero MAB, et al. 826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial. Annals of Oncology. 2022; 33: S926.